Company Profile

Isoplexis Inc (AKA: Isoplexis Corporation)
Profile last edited on: 12/2/2023      CAGE: 6XCE6      UEI: FRM2JMLMGJK1

Business Identifier: Single-cell detection system identifying patient immune responses
Year Founded
First Award
Latest Award
Program Status
Active (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

35 Ne Industrial Road
Branford, CT 06405
   (203) 208-4111
Location: Single
Congr. District: 03
County: New Haven

Public Profile

Previously located in Wilmington DE and now moved to Brandford. CT, IsoPlexis (NASDAQ:ISO) - an active SBIR player for some time after start-up continuing into early 2023 - - is a life sciences company developing a diagnostic platform to measure cellular immune responses in patients. With research areas emcompassing cell engineering & therapy, checkpoint & combination Immunotherapies, vaccines & immunology research, Iinflammatory & autoimmune disease and solid tumor & oncology, the company’s single-cell immune biomarkers are used to detect cellular responses at the single cell level to help determine individual therapeutic response. Originally spun out of Yale, the firm is developing a diagnostic platform to accelerate immunology research and therapeutic development assessing safety and efficacy of therapeutics, and monitoring disease progression - effectively enabling improved therapeutic development and informing physician decisions. Mostly focused to highly sensitive, multiplexed single-cell analysis tools for the life sciences, the firm's specialties include 'secretomic' analysis (in situ proteomics) for applications in immune monitoring, vaccine response evaluation, personalized medicine, adoptive immune therapies, stem cell research (including iPS), and oncology (including diagnostic tumor progression).. In early January 2023 it was announced that Berkeley Lights (Nasdaq: BLI), a life sciences tools company, and SBIR-active IsoPlexis (Nasdaq: ISO), - a company empowering labs to leverage the cells and proteome changing the course of human health - a definitive agreement had been made under which Berkeley Lights will acquire IsoPlexis in an all-stock transaction valued at $57.8 million.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Rong Fan -- Co-Founder and Chair

  Sean Mackay -- Chief Executive Officer & Co-Founder + DireCTOr

  Michael Aiello -- VP of Finance

  Kara Brower -- Co-Founder

  Carrie Carter -- Chief of Staff

  Lynne Frick -- VP of Business Development

  Timothy S McConnell

  Richard Rew -- SVP, General Counsel & Secretary

  Peter Siesel -- Chief Commercial Officer

  Verna Siu -- VP of Sales Operations and BD

  Maithreyan Srinivasan -- Consulting Chief Technology Officer

  John Strahley -- Chief Financial Officer

  Peter Tsiomplikas -- Director of Automation

  Rui Zheng

  Jing Zhou -- VP Immunology

Company News